Suspension of trading
Safe S.A. Stock Deutsche Boerse AG
Stocks
OR9
FR001400ZU25
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Delayed
Deutsche Boerse AG
02:05:11 2026-07-01 EDT
|
5-day change | 1st Jan Change | ||
| 0.4900 EUR | -2.00% |
|
-.--% | -75.50% |
| 06-30 | Safe Group sharply improves its full-year results | |
| 06-28 | Safe Orthopaedics SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 128K 148K 120K 109K 206K 14.14M 206K 1.42M 553K 7.14M 556K 543K 23.67M | P/E 2024 * |
-
| P/E 2025 | -0.07x |
|---|---|---|---|---|---|
| Enterprise Value | 13.24M 15.36M 12.41M 11.33M 21.35M 1.47B 21.41M 147M 57.46M 741M 57.69M 56.43M 2.46B | EV / Sales 2024 |
2.39x | EV / Sales 2025 | 2.47x |
| Free-Float |
87.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.00% | ||
| 3 months | +4.26% | ||
| 6 months | -37.18% | ||
| Current year | -75.50% |
| Current year | 0.4 | 1.65 | |
| 1 year | 0.4 | 2 | |
| 3 years | 0.1 | 134,713.47 | |
| 5 years | 0.1 | 10,000,000,000 | |
| 10 years | 0.1 | 10,000,000,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nicolas Papillon
CEO | Chief Executive Officer | 46 | - |
Thomas Droulout
CTO | Chief Tech/Sci/R&D Officer | 50 | 2010-02-14 |
| Director of Finance/CFO | - | 2017-11-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Droulout
BRD | Director/Board Member | 50 | - |
| Director/Board Member | - | 2019-11-25 | |
Ismaël Nujurally
BRD | Director/Board Member | 69 | 2019-11-25 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.00% | -.--% | - | - | 149K | ||
| +2.07% | -0.21% | -15.63% | +18.13% | 124B | ||
| -0.93% | -0.65% | -22.84% | -0.98% | 12.26B | ||
| -1.96% | -2.89% | +85.94% | +142.56% | 10.72B | ||
| +0.28% | -3.12% | -50.49% | -68.68% | 4.21B | ||
| -0.42% | +1.76% | -16.33% | +56.71% | 2.73B | ||
| +1.16% | -1.06% | -32.54% | -71.78% | 1.76B | ||
| -0.45% | -3.30% | -19.33% | -13.90% | 1.63B | ||
| -5.12% | -9.19% | -40.28% | -40.63% | 1.6B | ||
| Average | -0.85% | -0.57% | -13.94% | +2.68% | 19.81B | |
| Weighted average by Cap. | +1.34% | -1.41% | -10.73% | +21.51% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.04M 5.85M 4.73M 4.31M 8.13M 559M 8.15M 56.08M 21.88M 282M 21.96M 21.49M 936M | 5.36M 6.22M 5.03M 4.59M 8.65M 595M 8.68M 59.67M 23.28M 300M 23.37M 22.86M 996M |
| Net income | -1.93B -2.24B -1.81B -1.65B -3.11B -214B -3.12B -21.46B -8.37B -108B -8.41B -8.22B -358B | -4.67M -5.42M -4.38M -4M -7.54M -518M -7.56M -51.99M -20.29M -262M -20.37M -19.92M -868M |
| Net Debt | 11.47M 13.31M 10.76M 9.82M 18.5M 1.27B 18.55M 128M 49.79M 642M 49.98M 48.89M 2.13B | 13.11M 15.22M 12.29M 11.22M 21.14M 1.45B 21.21M 146M 56.91M 734M 57.13M 55.89M 2.43B |
Employees
87
- Stock Market
- Stocks
- ALSAF Stock
- OR9 Stock
Select your edition
All financial news and data tailored to specific country editions
















